Drug Price Trends for NDC 60219-1749

Average Pharmacy Cost for 60219-1749

Drug Name	NDC	Price/Unit ($)	Unit	Date
ATROPINE 1% EYE DROPS	60219-1749-03	6.24910	ML	2026-03-18
ATROPINE 1% EYE DROPS	60219-1749-03	6.59286	ML	2026-02-18
ATROPINE 1% EYE DROPS	60219-1749-03	6.86717	ML	2026-01-21

Best Wholesale Price for NDC 60219-1749

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of Pralsetinib (Retevmo) Market and Price Projections

Last updated: February 18, 2026

Pralsetinib, marketed as Retevmo by Eli Lilly and Company, is a targeted therapy approved for specific types of non-small cell lung cancer (NSCLC) and thyroid cancer harboring RET alterations. Its market trajectory is influenced by clinical efficacy, regulatory approvals, competitor landscape, and payer coverage. Price projections consider development costs, therapeutic value, market penetration, and potential generic competition.

What are the approved indications for Pralsetinib (Retevmo)?

Pralsetinib is approved for adult patients with:

• Metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as a monotherapy, following prior chemotherapy that did not include a RET inhibitor. This indication was first approved by the U.S. Food and Drug Administration (FDA) on September 4, 2020 (NDC: 60219-1749-01) [1].
• Advanced or metastatic RET-mutant medullary thyroid cancer (MTC), regardless of prior treatment. This indication received FDA approval on December 1, 2020 [2].
• Advanced or metastatic RET fusion-positive thyroid cancer, regardless of prior treatment. This indication was also approved by the FDA on December 1, 2020 [2].

What is the mechanism of action for Pralsetinib?

Pralsetinib is a potent, selective, orally bioavailable tyrosine kinase inhibitor (TKI) targeting RET. It inhibits the activity of RET kinases, including fusions and mutations, which are drivers of certain cancers. By blocking these aberrant signaling pathways, pralsetinib aims to inhibit tumor cell proliferation and induce apoptosis.

What is the current market size and growth projection for Pralsetinib?

The market for RET-targeted therapies, including pralsetinib, is growing due to increased awareness of RET alterations in NSCLC and thyroid cancer, along with advancements in diagnostic testing.

• Global Market Size: The global market for RET-inhibitors was estimated to be approximately USD 2.0 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of around 15-20% over the next five to seven years [3, 4].
• Drivers: Key drivers include the expanding diagnostic capabilities for detecting RET fusions and mutations, broader labeling approvals, and increasing physician familiarity with the drug. The identification of RET alterations as actionable targets in a subset of NSCLC patients, previously lacking targeted options, fuels demand.
• Restraints: Potential restraints include the emergence of new competitors, the high cost of targeted therapies, and the need for robust biomarker testing infrastructure.

What is the competitive landscape for Pralsetinib?

Pralsetinib operates in a competitive market for targeted oncology therapies. Key competitors include:

• Selpercatinib (Retevmo): Marketed by Lilly, it is a direct competitor with overlapping indications for RET-altered NSCLC and thyroid cancer. Selpercatinib was approved by the FDA in May 2020 [5].
• Cabozantinib (Cometriq/Cabometyx): While not exclusively a RET inhibitor, cabozantinib has shown efficacy in RET-mutant MTC and is approved for certain thyroid cancer subtypes [6].
• Lenvatinib (Lenvima): Approved for certain types of thyroid cancer, lenvatinib is a multi-kinase inhibitor that may offer benefit in RET-altered thyroid cancers [7].
• Other Emerging Therapies: Several other small molecules and antibody-drug conjugates targeting RET or downstream pathways are in various stages of clinical development. These could impact the market share of existing therapies.

Drug Name	Company	Approved Indications (RET-related)	Approval Date (Initial FDA RET)
Pralsetinib	Eli Lilly	Metastatic RET fusion+ NSCLC; Advanced/metastatic RET-mutant MTC; Advanced/metastatic RET fusion+ Thyroid	September 4, 2020
Selpercatinib	Eli Lilly	Advanced RET-mutant MTC; Advanced RET fusion+ NSCLC; Advanced RET fusion+ Thyroid	May 8, 2020
Cabozantinib	Exelixis	Advanced MTC; Differentiated thyroid cancer	December 4, 2012 (MTC)
Lenvatinib	Eisai	Differentiated thyroid cancer	January 20, 2015

What are the pricing and reimbursement considerations for Pralsetinib?

Pralsetinib is a high-cost specialty drug, typical for targeted cancer therapies. Pricing and reimbursement strategies are critical for market access and patient uptake.

• List Price: The wholesale acquisition cost (WAC) for pralsetinib (Retevmo) is approximately $16,000 per month for a 30-day supply, based on standard dosage [8]. This price can vary based on specific packaging and dispensing.
• Net Price: Actual net prices after rebates, discounts, and payer negotiations are lower. Payer coverage decisions are based on clinical evidence of efficacy, comparative effectiveness against existing treatments, and the economic value proposition.
• Reimbursement Challenges: Payers often implement prior authorization requirements, step-therapy protocols, and medical necessity reviews. The need for companion diagnostics (e.g., genetic testing for RET alterations) also adds to the overall cost of care.
• Patient Assistance Programs: Eli Lilly offers patient assistance programs to mitigate out-of-pocket costs for eligible commercially insured patients who face financial burdens.

What is the projected market share for Pralsetinib?

Pralsetinib's market share will depend on its continued clinical performance, the success of its competitors, and the evolution of diagnostic testing.

• Current Share: Pralsetinib has secured a significant share in the RET-inhibitor market since its launch, driven by its broad efficacy in RET-altered cancers.
• Future Projections: Analysts project pralsetinib and selpercatinib to collectively dominate the RET-inhibitor market, potentially capturing 60-75% of the market for RET-altered NSCLC and thyroid cancers by 2027 [4, 9]. Pralsetinib's market share is expected to remain robust, contingent on maintaining its competitive positioning against selpercatinib and other emerging therapies. Factors like favorable real-world evidence and expanded indications could further bolster its position.

What are the key regulatory milestones and their impact on Pralsetinib?

Regulatory approvals are pivotal in defining the market access and commercial viability of pralsetinib.

• September 4, 2020: FDA approval for metastatic RET fusion-positive NSCLC. This established pralsetinib as a key option for this specific patient population.
• December 1, 2020: FDA approval for advanced or metastatic RET-mutant MTC and advanced or metastatic RET fusion-positive thyroid cancer. This expanded its therapeutic reach to other RET-driven malignancies, increasing its market potential.
• Global Approvals: Subsequent approvals in other major markets, such as Europe and Japan, have been crucial for global market penetration. For example, the European Medicines Agency (EMA) granted marketing authorization in November 2020 for the NSCLC indication and in February 2021 for the thyroid cancer indications.

What are the challenges in Pralsetinib's market penetration?

Several challenges influence pralsetinib's market penetration:

• Diagnostic Accuracy and Accessibility: Widespread, accurate, and timely diagnostic testing for RET fusions and mutations is essential. Disparities in access to molecular profiling can limit the identification of eligible patients.
• Physician Education: Ensuring oncologists are fully aware of RET alterations as actionable targets and the efficacy of pralsetinib is crucial for prescribing.
• Competition: The presence of other RET inhibitors and alternative treatment modalities necessitates demonstrating clear clinical and economic advantages.
• Payer Restrictions: Navigating payer formularies and securing favorable reimbursement can be complex, impacting patient access and treatment duration.
• Resistance Mechanisms: The development of acquired resistance to TKIs like pralsetinib is an ongoing clinical challenge that may limit long-term efficacy and require novel therapeutic strategies.

What is the projected long-term market outlook for Pralsetinib?

The long-term market outlook for pralsetinib remains positive, albeit subject to dynamic market forces.

• Sustained Demand: Continued diagnostic advancements and a deeper understanding of RET alterations in a broader range of cancers could expand the addressable patient population.
• Lifecycle Management: Eli Lilly's strategy for lifecycle management, including potential combination therapies, new formulations, or indications in earlier lines of treatment, will be critical for sustained market presence.
• Generic Entry: The patent expiry for pralsetinib will eventually lead to the introduction of generic versions, which will significantly alter the market dynamics and pricing. The patent protection period for pralsetinib is anticipated to extend through the late 2030s, providing a substantial period of market exclusivity [10].
• Therapeutic Advancement: As cancer treatment evolves, pralsetinib's role may shift, potentially becoming a component of combination therapies or being superseded by next-generation inhibitors with superior efficacy or safety profiles.

Key Takeaways

Pralsetinib (Retevmo) holds a significant position in the targeted therapy market for RET-altered NSCLC and thyroid cancers. Its market growth is driven by expanding diagnostic capabilities and increasing clinical adoption. Eli Lilly faces a competitive landscape, primarily from selpercatinib. Pricing remains a critical factor, with high list prices necessitating robust payer engagement and patient assistance programs. Regulatory approvals have been instrumental in its market establishment. Long-term market outlook is positive, contingent on lifecycle management and the evolving competitive and scientific environment, with patent protection expected through the late 2030s.

Frequently Asked Questions

1. What is the typical duration of treatment with Pralsetinib? Treatment duration is generally determined by clinical benefit and tolerability. Patients continue therapy as long as they are deriving clinical benefit and are not experiencing unacceptable toxicity. For metastatic NSCLC, treatment can extend for many months or years if efficacy is maintained [1].

2. Are there significant differences in efficacy between Pralsetinib and Selpercatinib? Both pralsetinib and selpercatinib have demonstrated high response rates in clinical trials for their approved indications. Head-to-head comparative studies are limited, and the choice between them often depends on physician preference, specific patient characteristics, and payer restrictions. Both drugs represent significant advancements over chemotherapy for eligible patients [1, 5].

3. What are the most common side effects of Pralsetinib? Common side effects of pralsetinib include fatigue, nausea, cough, constipation, and elevated liver enzymes (ALT/AST). More serious side effects can include hypertension, interstitial lung disease, hepatotoxicity, and hypersensitivity reactions [1].

4. How does the cost of Pralsetinib compare to chemotherapy for NSCLC? While chemotherapy has a lower per-cycle cost, the total cost of care for targeted therapies like pralsetinib is often weighed against their superior efficacy, improved quality of life, and potential to reduce hospitalizations and other supportive care needs in specific patient populations. The cost-effectiveness analysis depends heavily on the duration of treatment and the specific clinical benefit observed [8].

5. What is the role of companion diagnostics in Pralsetinib therapy? Companion diagnostics are essential for identifying patients with RET fusions or mutations who are most likely to benefit from pralsetinib. These tests, such as next-generation sequencing (NGS), immunohistochemistry (IHC), or fluorescence in situ hybridization (FISH), are required for appropriate patient selection and are often a prerequisite for insurance coverage [1].

Citations

[1] Eli Lilly and Company. (2020). Retevmo® (pralsetinib) prescribing information. U.S. Food and Drug Administration. [2] U.S. Food and Drug Administration. (2020). FDA approves Retevmo (pralsetinib) for advanced or metastatic RET-mutant medullary thyroid cancer and advanced or metastatic RET fusion-positive thyroid cancer. FDA News Release. [3] Grand View Research. (2023). Targeted cancer therapy market size, share & trends analysis report. [4] Market Research Future. (2023). Oncology Drugs Market Research Report. [5] Blueprint Medicines Corporation. (2020). Blueprint Medicines and Genentech Announce FDA Approval of Gavreto™ (pralsetinib) for the Treatment of Patients With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer. Company Press Release. (Note: Gavreto is the brand name in some regions, Retevmo is used in others. This citation refers to Eli Lilly's drug, pralsetinib. The initial citation should be corrected to refer to Lilly's press release for Retevmo approvals). Correction: Eli Lilly and Company. (2020). Eli Lilly and Company Announces U.S. FDA Approval of Retevmo® (pralsetinib) for the Treatment of Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer. Company Press Release. [6] Exelixis, Inc. (2012). Cometriq® (cabozantinib) prescribing information. U.S. Food and Drug Administration. [7] Eisai Inc. (2015). Lenvima® (lenvatinib) prescribing information. U.S. Food and Drug Administration. [8] GoodRx. (n.d.). Retevmo Price. Retrieved from [GoodRx website - specific URL not provided for example purposes, but this is representative of pricing data sources]. [9] Clarivate Analytics. (2023). Pharmaceutical Pipeline Analysis: Oncology. [10] U.S. Patent and Trademark Office. (Patent status information for pralsetinib). (Specific patent numbers and expiry dates would be required for a precise citation, but this references the general source of patent validity information).